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Healers have been treating heart failure (HF) for millennia, but the central role of
neurohormonal abnormalities in its pathogenesis and management was discovered only
recently.1 HF previously was understood almost entirely as the result of structural and
functional abnormalities of the heart. In the eighteenth century, anatomists described gross
enlargement of failing hearts removed at autopsy, and concluded rightly that hypertrophy
was central to the pathobiology of HF. Technological advances in the early twentieth
century permitted evaluation of the beating heart, and the field of cardiac physiology
evolved. As a result, HF came to be conceived in mechanical terms: the fundamental insult
in the failing heart was impaired contractility, and this abnormality was either exacerbated
or alleviated by alterations in load. Structure and function reconciled well in animal
physiology laboratories, because the hypertrophied and failing heart both resulted from and
led to altered loading conditions.
The essential role of neurohormonal disturbances in human HF was recognized first in the
1970s and brought to prominence in the 1980s and 1990s.2 In this conception of HF,
circulating substances synthesized in the heart, kidneys, adrenal glands, and pituitary glands
engendered the characteristic anatomic and physiologic abnormalities described by earlier
researchers. HF was no longer simply a disease of the heart.
© 2014 Elsevier Inc. All rights reserved.
*Corresponding author. bcjensen@med.unc.edu.
1These authors contributed equally.
Disclosure: The authors have no relevant financial disclosures.
NIH Public Access
Author Manuscript
Heart Fail Clin. Author manuscript; available in PMC 2015 October 01.
Published in final edited form as:






















Increased levels of aldosterone and vasopressin explained the chronically increased preload
in the failing heart; norepinephrine and angiotensin (Ang) II induced pathologic hypertrophy
and detrimental increases in afterload.
Randomized clinical trials (another important technological advance) reinforced the
neurohormonal paradigm. In 1987, the CONSENSUS (Cooperative North Scandinavian
Enalapril Survival Study) showed a 31% reduction in 1-year mortality in patients with end-
stage HF treated with the angiotensin-converting enzyme (ACE) inhibitor, enalapril,
confirming the importance of Ang II in the progression of HF.3 The use of beta-adrenergic
receptor blockers (β-blockers) in HF was described first in 1981,4 although the first large
mortality trial of β-blockers in HF was the MDC (Metoprolol in Dilated Cardiomyopathy)
trial, published in 1993.5 MDC was followed in the next decade by the MERIT-HF
(Metoprolol CR/XL Randomized Intervention Trial in Congestive Heart Failure), the US
Carvedilol HF trials, CIBIS (Cardiac Insufficiency Bisoprolol Study) I and II, and
COPERNICUS (Carvedilol Prospective Randomized Cumulative Survival) trial, collectively
proving that β-blockers improve survival in HF (reviewed in Ref.6).
In many respects, clinical trial data have provided the strongest endorsement of the
neurohormonal paradigm. Drugs that alter hemodynamic parameters without blocking
neurohormonal activation, including digoxin,7 non–potassium-sparing diuretics,8 and
positive inotropes,9 have either neutral or negative effects on survival. In this respect, the
contemporary use of neurohormonal modulators for HF pharmacotherapy offers an excellent
example of reciprocity in translational science: elucidation of basic pathophysiology directs
therapeutic targeting, and clinical trial results further inform the understanding of drug
mechanism. This article discusses mechanisms of action for neurohormonal antagonists,
with attention to both fundamental physiology and clinical trial outcomes.
THE SYMPATHETIC NERVOUS SYSTEM AND CARDIOVASCULAR
PHYSIOLOGY
The sympathetic nervous system (SNS) is activated via arterial and venous baroreceptors
and arterial chemoreceptors in response to decreases in perfusion pressure or oxygen
delivery. In response, efferent fibers increase the release of norepinephrine (NE) (80%) or
epinephrine (EPI) (20%) from synaptic varicosities in the myocardium and blood vessels,
and stimulate the adrenal medulla to release NE (20%) and EPI (80%) into the blood. These
hormones bind at least 9 different subtypes of adrenergic receptors (ARs) (3 beta-ARs [β1,
β2, β3], 3 alpha-1 ARs [α1A, α1B, α1D], and 3 alpha-2 ARs [α2A, α2B, α2C]) that are
expressed variably by most cell types in the cardiovascular system and function primarily
through G protein–coupled signaling cascades (Fig. 1).10
β1-ARs predominate in the myocardium (70%–80% of total β-ARs), whereas β2-ARs and
β3-ARs are less abundant (15%–18% and 2%–3% respectively) (see Fig. 1A).11 The
predominant β-AR in vascular tissue is β2-AR, which mediates vasorelaxation (see Fig. 1B).
Stimulation of β1-ARs on cardiomyocytes activates stimulatory G protein (Gs) and protein
kinase A (PKA), leading to increased contractility (via activation of L-type calcium channels
and ryanodine receptors); heart rate (via stimulation of L-type calcium channels and
Reed et al. Page 2






















hyperpolarization-activated cyclic nucleotide-gated [HCN] channels); and rate of relaxation
(via indirect stimulation of sarcoplasmic/endoplasmic reticulum calcium ATPase [SERCA]
and Na/K-ATPase). Cardiomyocyte β2-AR activation also increases inotropy, although
these receptors are less abundant and have a lower affinity for NE. The β2 is the
predominant AR on cardiac fibroblasts, in which it likely plays important roles in HF
pathobiology. β3-ARs exert an exclusively negative inotropic effect through activation of
nitric oxide.12
α1-ARs are best known for their effects in vascular smooth muscle, where they promote
vasoconstriction through activation of Gq, although myocardial α1-ARs mediate broadly
beneficial effects, including positive inotropy, physiologic cardiomyocyte hypertrophy, and
protection from cell death.13 α2-ARs are predominantly found in presynaptic terminals of
adrenergic neurons and adrenal chromaffin cells, where they inhibit NE/EPI release via Gi-
related signaling cascades that inhibit PKA activation.11,14 In this respect, α2-ARs
negatively regulate excess NE/EPI release and spillover in both central and peripheral
adrenergic synapses.
THE SNS AND HF PATHOPHYSIOLOGY
Chronic catecholamine excess is central to the pathobiology of HF, and the degree of
activation is directly proportional to disease severity.15,16 SNS upregulation also extends to
the central nervous system, where NE spillover and turnover is increased.17,18 In the
periphery, SNS upregulation is organ specific: it is preferentially activated in cardiac tissue
in mild to moderate HF, and only becomes activated in the kidney and other organ systems
in severe HF.19,20
Chronic activation of cardiac β-ARs leads to pathologic cardiac hypertrophy and fibrosis:
the hallmarks of ventricular remodeling. Increased levels of both local and circulating
catecholamines lead to cardiac hypertrophy by acting directly on the cardiomyocyte β1-
ARs21 or by stimulating the paracrine release of other hormones such as Ang II and
endothelin-1 (ET-1).22 SNS activation also leads to direct stimulation of β2-ARs on cardiac
fibroblasts, leading to fibroblast proliferation and increased release of cytokines such as
interleukin-6, and hormones such as Ang II and ET-1. These factors in turn lead to increased
collagen deposition, fibrosis, pathologic differentiation of fibroblasts into myofibroblasts,
and cardiomyocyte hypertrophy.23 Furthermore, chronic β1-AR hyperstimulation in animal
models leads to necrotic and apoptotic cardiomyocyte death, implicating sustained SNS
activity in another important cellular mechanism of HF.24
Upregulation of the SNS can also cause ventricular arrhythmias25 via direct effects on
cardiomyocyte calcium handling mediated in part by catecholamine-induced ryanodine
receptor dysfunction.26 Chronic catecholamine surge can also promote both atrial and
ventricular arrhythmias in HF indirectly through increased fibrosis and remodeling.27
Chronic myocardial β1-AR activation ultimately results in the depletion of NE from cardiac
nerve terminals, and downregulation of myocardial β-ARs.28 The desensitization and
inactivation of membrane-bound β-ARs is performed by G protein–coupled receptor kinases
(GRKs) that phosphorylate ARs, facilitating binding to beta-arrestins that uncouple the
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receptor from G proteins and target it for internalization.10 The downregulation of both
myocardial and presynaptic ARs results in decreased cardiac inotropic reserve, further
disabling the failing heart. Inhibition of β1-AR downregulation by blocking GRK2 activity
improves cardiac function and myocyte survival,29 providing further evidence that the
diminution of β-AR signaling is at least partially responsible for the pathogenesis of HF.
Inhibitors of the SNS
The success of β-blocker therapy offers perhaps the clearest example of the critical role of
neurohormones in HF. Physiologic studies in animals and humans conclusively show
negative inotropy resulting from acute β-AR antagonism,30,31 and clinical guidelines
historically contained a contra-indication for β-blocker use in patients with HF.32
Nevertheless, studies in cells and animals established the fundamental role of chronic NE
exposure in the pathophysiology of HF (reviewed in Ref.33), leading to the incremental
translation to clinical trials and practice.
Three β-blockers currently are approved for use in HF: metoprolol succinate, carvedilol, and
bisoprolol. These drugs were selected from randomized clinical trial evidence, although
debate exists about whether the specific pharmacology of these agents confers superiority or
whether β-blocker benefits arise purely from antagonism of the β1-AR.34,35 No trial has
convincingly tested head-to-head efficacy of multiple β-blockers in HF.36
β-Blockers can be classified broadly based on selectivity for AR subtypes, vasodilating
effects, and intrinsic sympathomimetic or sympatholytic properties (Table 1). First-
generation β-blockers are not as well-tolerated in patients with HF, possibly as a result of
blockade of vascular β2 receptors, which may shunt catecholamines to α1 receptors and
cause vasoconstriction.37 Second-generation β-blockers are considered cardioselective
because of their selectivity for β1-ARs.
Third-generation β-blockers generally are distinguished from first-generation agents by their
vaso-dilating effects. Nebivolol causes vasodilation by stimulating nitric oxide release,
possibly through β3-AR activation. Bucindolol is a nonselective β-blocker with intrinsic
sympatholytic activity and weak α1-blocking properties. Carvedilol blocks β1-ARs, β2-ARs,
and α1-ARs, and is the most widely studied of these agents. Although the benefits of
carvedilol have been attributed widely to afterload reduction resulting from α1-AR
antagonism, this effect dissipates within weeks.41 Thus, carvedilol’s beneficial effects likely
are caused primarily by β1-blockade, although it also has adaptive effects on cellular
metabolism, oxidative stress reduction, and protection from apoptotic cell death.45,46
Mechanisms of β-Blocker Benefit in the Human Heart
Underlying mechanisms for the benefits of β-blockers in HF have not been elucidated
completely, but likely are complex and multifactorial given the broadly pathologic effects of
chronic catecholamine surge (Table 2).
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Acute blockade of myocardial β1-ARs has negative inotropic and chronotropic effects.
Chronic β-blocker use improves cardiac performance in patients with HF, possibly because
negative chronotropy increases filling time.66 Heart rate reduction has been used as an index
of β-blocker efficacy and a meta-analysis of 23 randomized clinical trials indicates that heart
rate reduction is a more powerful predictor of benefit than β-blocker dose. For every heart
rate decrease of 5 beats per minute in the pooled β-blocker groups there was an 18%
reduction in risk of death.47 The early success of the specific HCN channel blocker
ivabradine,67 which slows heart rate without modulating the SNS, may corroborate the
primary importance of negative chronotropy in HF therapy.
Chronic β-blocker use does not decrease contractile function in patients with HF. Invasive
hemodynamic studies show improved stroke volume and cardiac index, at rest and peak
exercise, after chronic carvedilol treatment.68 A meta-analysis of 21 randomized clinical
trials found an absolute increase in ejection fraction of 4% in patients with HF treated with
β-blocker relative to placebo,34 and a separate analysis of 18 trials reported a 29% relative
increase in ejection fraction.25 Ex vivo experiments on failing human heart tissue suggest
that β-blocker use improves inotropic response to β-AR agonists and restores aspects of
physiologic cardiomyocyte calcium handling69 and responsiveness.70 β-Blockers also
improve the diastolic performance of the hypertrophied human heart.71
Reverse remodeling
Numerous clinical trials show the favorable effect of chronic β-blocker use on ventricular
remodeling. In a MERIT-HF substudy, left ventricular (LV) end-diastolic volume index
decreased by 17% and LV mass index decreased by almost 10% after 6 months of
metoprolol.48 Metoprolol also decreased LV end-diastolic index by 10% to 15% in patients
with asymptomatic LV dysfunction in the REVERT (Reversal of Ventricular Remodeling
with Toprol-XL) study.49 Both CAPRICORN50 and the Australia–New Zealand HF
Research Collaborative Group51 showed similar improvements with carvedilol.
β-Blockers decrease fibrosis in animal models of HF72,73 and reduce circulating markers of
fibrosis in humans,74 although direct effects are not readily demonstrable in human hearts,
perhaps because the β2-AR is the predominant AR on cardiac fibroblasts.
Antiarrhythmic effects
Sudden cardiac death is the primary cause of mortality in patients with New York Heart
Association class I - III HF, and the well-established antiarrhythmic effects of β-blockers
also contribute to their survival benefit. Although sudden cardiac death was not reduced in
all trials of β-blockade in HF, a reduction was seen in the BHAT (Beta-Blocker Heart Attack
Trial),75 CAPRICORN,76 CI-BIS II,38 and MERIT-HF.39 A recent meta-analysis of 30 trials
(24,779 patients) of β-blockers in HF found a 31% reduction in the risk of sudden cardiac
death (odds ratio, 0.69; 95% confidence interval, 0.62–0.77) with a number needed to treat
of 43 patients to prevent 1 sudden cardiac death per year.52 β-Blocker use also substantially
decreases the risk of both appropriate53 and inappropriate defibrillator therapies.54
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Molecular changes in human heart
Chronic β-blocker use in HF mitigates the characteristic decrease in myocardial β-AR
abundance, although it is unclear whether this effect is essential for clinical or physiologic
benefit.66,77 β-Blocker use also abrogates the pathologic changes in gene expression in the
failing heart: α-myosin heavy chain abundance increases, β-myosin heavy chain decreases,
and sarcoplasmic reticulum Ca2+ ATPase levels are restored.77
Digoxin and the SNS
In the past, the usefulness of digoxin in HF has been attributed to its positive inotropic
effects. However, these effects are only present at high serum digoxin concentrations (>1 ng/
mL), at which an increased risk of mortality has also been observed.78 It has been proposed
that the benefits of digoxin at lower concentrations result in part from neurohormonal
modulation. Among its many pharmacologic actions, digoxin decreases circulating
norepinephrine and renin levels79,80 and has a favorable impact on natriuretic peptide
release.81
Risks of sympatholysis in HF
Although the essential role of catecholamine excess in the pathophysiology of HF is beyond
dispute, direct sympatholytic therapies have been associated with poorer outcomes. In a
study of patients with chronic HF, a sustained-release preparation of moxonidine, an
imidazoline receptor agonist that reduces sympathetic outflow, improved ventricular
performance but led to an increase in serious adverse events.82 These risks were confirmed
in a larger trial, which was terminated early because of a nearly 2-fold increase in death
among those randomized to moxonidine.83 The intrinsic sympatholytic properties of
bucindolol may help explain why outcomes in the BEST (Beta-Blocker Evaluation in
Survival Trial) were less favorable than those of other β-blocker clinical trials.44
One conceivable explanation for the apparent risk associated with sympatholysis is the
abrogation of adaptive effects of myocardial α1-AR activation. Evidence from human
studies suggests that the relative increase in α1-AR expression observed in advanced HF
may be a compensatory response to preserve myocardial function in the setting of β1-AR
downregulation and dysfunction.84 These cardioprotective effects may explain why
therapies that inhibit α1-ARs have been linked to adverse outcomes in patients with HF. An
arm of ALLHAT that randomized patients to the α1-blocker doxazosin was stopped early
for a 2-fold increase in incident HF.85
THE RENIN-ANGIOTENSIN-ALDOSTERONE SYSTEM AND
CARDIOVASCULAR PHYSIOLOGY
The renin-angiotensin-aldosterone system (RAAS) consists of a protease cascade that is
activated by renin release from the juxtaglomerular cells of renal afferent arterioles. Renin is
secreted in response to decreased renal perfusion pressure, decreased salt delivery to the
distal convoluted tubule, increased renal sympathetic nerve activity, or changes in
circulating natriuretic peptides. Renin catalyzes the cleavage of angiotensinogen, a
circulating protein produced by the liver. The resulting peptide, angiotensin I (Ang I), is then
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cleaved by ACE, to generate Ang II, which is among the most potent endogenous
vasoconstrictors. Ang II binds to 2 G protein–coupled receptors, angiotensin II receptor,
type I (AT1) and AT2. AT1 is the primary receptor expressed on vascular smooth muscle,
endothelium, myocardium, neurons, and fibroblasts, whereas AT2 is primarily expressed
early in development and its effects are less well understood in adults.86,87
The other potent effector hormone of RAAS, aldosterone, is a steroid hormone released
primarily from the adrenal cortex in response to increased Ang II and plasma [K+].
Aldosterone binds to the intracellular mineralocorticoid receptor (MR) leading to increased
salt and water reabsorption, increased blood volume, and alterations in ion-channel
expression.88
In the past, RAAS-associated hormones were considered to be renally controlled endocrine
hormones that exerted effects widely throughout the body. However, it is now well
understood that tissues such as the heart, blood vessels, lungs, and brain have an intrinsic
RAAS that functions in an autocrine/paracrine manner.89 In the heart, local stress, cellular
damage, and stretch can each lead to an upregulation of locally produced RAAS components
including ACE, Ang II, and aldosterone.90,91 It is now thought that cardiac-generated RAAS
components play a major role in the progression of HF.92
THE RAAS AND HF PATHOPHYSIOLOGY
Circulating and intrinsic Ang II and aldosterone are increased in HF, and contribute to HF
pathophysiology through both extracardiac and direct cardiac effects.92,93 In vascular tissue,
Ang II and aldosterone mediate increased vasoconstriction, unfavorable vascular
remodeling, and endothelial dysfunction (Fig. 2B).94,95 Ang II and aldosterone promote
sodium and water reabsorption in the proximal and distal convoluted tubules respectively.
RAAS hormones also have important direct effects on myocardial cells.96 Ang II induces
cardiomyocyte hypertrophy and cardiac fibroblast proliferation through activation of AT1
receptors,97 promoting cardiac hypertrophy independent of effects on blood pressure.98
Aldosterone also promotes cardiac fibrosis through activation of mineralocorticoid receptors
on cardiac fibroblasts (see Fig. 2A).
In addition to the directly deleterious effects of Ang II and aldosterone, RAAS also interacts
with other neurohormonal signals that contribute to the pathobiology of HF. For example,
local Ang II production leads to increased NE release from sympathetic nerve terminals in
the heart.99 Ang II also has effects on the central nervous system, causing a central
activation of sympathetic nerves that target the cardiovascular system.100 Central inhibition
of AT1 receptors leads to a decrease in sympathetic nerve activity in the heart.101
In addition to these well-known RAAS constituents, several other RAAS enzymes
contribute to cardiovascular regulation. ACE2, neprilysin (also known as neutral
endopeptidase),87 prolylendo-peptidases, and prolylcarboxypeptidases break down Ang I
and II, ultimately leading to the generation of a peptide known as Ang(1–7).87 Ang(1–7)
acts on its own receptor, MasR, counteracting the effects of Ang II by causing vasodilation,
decreased fibrosis, decreased oxidative stress, and decreased hypertrophy.102 In addition to
cleaving Ang I, ACE also is the main enzyme that breaks down the vasodilator bradykinin.
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It has been proposed that one of the key mechanisms of ACE inhibitors in the treatment of
HF is increasing bradykinin levels, directly leading to vasodilation and decreased
afterload.103 However, increased bradykinin is also responsible for several of the side effects
of ACE inhibitor treatment such as angioedema and dry cough.104
Inhibitors of the RAAS
Inhibitors of RAAS used in the management of HF include ACE inhibitors, angiotensin
receptor blockers (ARBs), and aldosterone receptor antagonists. ACE inhibitors prevent the
conversion of Ang I to Ang II, whereas ARBs competitively inhibit the effect of Ang II on
AT1 receptors in heart, kidney, and vascular tissue. Aldosterone receptor antagonists
competitively inhibit the binding of aldosterone to mineralocorticoid receptors in the heart,
kidney, and peripheral vasculature. The benefits of ACE inhibitors, ARBs, and aldosterone
receptor antagonists in HF are considered class-wide effects, because clinical trials of
multiple agents from each drug class show benefit. Higher doses of ACE inhibitors and
ARBs confer greater reductions in hospitalizations compared with lower doses,105,106 but
head-to-head comparisons between the two classes have been inconclusive.
Mechanisms of RAAS Blockade Benefit in Human HF
The benefits of RAAS antagonists initially were thought to result from their favorable
effects on loading conditions as mediated by activity in the kidney and peripheral
vasculature, but salutary direct myocardial effects are now recognized (see Table 2).
Hemodynamics
Decreased activation of vascular AT1 receptors by circulating Ang II produces vasodilation
and thus decreases cardiac afterload. In addition, less salt and water are retained as a result
of decreased downstream aldosterone release, thereby reducing preload. In one randomized
hemodynamic trial, fosinopril decreased pulmonary capillary wedge pressure (preload) and
systemic vascular resistance (afterload) acutely. After 10 weeks of therapy, preload and
afterload were durably reduced and cardiac index was increased compared with placebo.56
Aldosterone receptor antagonists cause a mild decrease in preload acutely through their
potassium-sparing diuretic effects. However, a clinically meaningful diuretic effect is less
commonly observed at the low doses used in HF and is unlikely to explain the magnitude of
benefit observed in clinical trials.
Reverse remodeling
ACE inhibitors and ARBs have uniformly favorable effects on cardiac remodeling in HF. In
the SOLVD (Studies of Left Ventricular Dysfunction) trial, 1 year of enalapril resulted in a
10% decrease in both LV end-diastolic and end-systolic volumes.57 Similar results were
reported with post-MI treatment with captopril in SAVE (Survival and Ventricular
Enlargement) trial.107 Losartan led to greater regression of LV hypertrophy than atenolol in
the LIFE (Losartan Intervention For Endpoint) trial,58 and treatment with valsartan led to
decreased ventricular volume and increased ejection fraction in Val-HeFT (Valsartan Heart
Failure Trial).55
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Aldosterone receptor antagonists reduced circulating markers of collagen turnover in both
RALES (Randomized Aldactone Evaluation Study) and EPHESUS (Eplerenone Post-AMI
Heart Failure Efficacy and Survival Trial), suggesting that inhibition of cardiac fibrosis
contributes to the benefit associated with both spironolactone and eplerenone.62,63 However,
aldosterone receptor antagonists do not consistently confer beneficial remodeling in clinical
trials.61
Antiarrhythmic effects
In contrast with β-blockers, there is no clear signal that ACE inhibitors or ARBs reduce
arrhythmias or sudden cardiac death in patients with HF.108 For example, in CONSENSUS
there was a 50% relative risk reduction in death caused by progressive HF, but no change in
sudden cardiac death after treatment with enalapril.3 Aldosterone blockade reduces the risk
of both atrial and ventricular arrhythmias, which may partly explain the reductions in sudden
cardiac death observed in clinical trials.64,65 This antiarrhythmic effect may be caused by
maintenance of physiologic serum potassium concentrations in the setting of aggressive loop
diuretic therapy or it may be an epiphenomenon of reverse remodeling and decreased
fibrosis.
Other effects
Animal studies reveal that ACE inhibitors have antiatherogenic effects resulting from
inhibition of vascular smooth muscle cell proliferation and restoration of endothelial
function.59 Results from clinical trials substantiate these findings. ACE inhibitors improved
post-MI outcomes in both SAVE and SOLVD and a large meta-analysis confirmed a 20% to
25% reduction in risk of acute coronary syndrome in patients with HF who received an ACE
inhibitor.60 ACE inhibitors also delay progression of renal dysfunction, which is a harbinger
of poor outcome in HF.109
ACE (aldosterone) escape
The efficacy of RAAS antagonists can diminish over time through an effect known as
aldosterone or ACE escape, whereby a maladaptive increase in RAAS components is
observed after chronic treatment with RAAS antagonists.110 ACE escape occurs in
approximately 10% of patients within 6 months and 50% of patients within 12 months of
starting treatment.111 There are several potential physiologic explanations for this
phenomenon. Prolonged inhibition of ACE or AT1 leads to increased levels of renin and
Ang I because of the loss of negative feedback by Ang II. In the setting of ACE inhibition,
several other enzymes such as chymase and cathepsin also cleave circulating and local Ang I
to Ang II, leading to aldosterone production (escape).104
Further, a receptor for renin and prorenin (inactive renin) has recently been discovered.
Binding of (pro)renin to the (pro)renin receptor (PRR) leads to increased fibrosis and release
of cytokines and prohypertrophic growth factors. PRR also serves an enzymatic function,
generating active renin from inactive (pro)renin.112
Multiple clinical trials have investigated the possibility that dual RAAS antagonist therapy
could abrogate ACE escape and improve outcomes in HF. Combined treatment with ACE
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inhibitor and ARB produced incremental improvements in cardiovascular mortality and
hospitalizations but was also associated with an increase in adverse events.113,114 Meta-
analysis of 4 published clinical trials of RAAS combination therapy found a 2-fold increased
risk of worsening renal function and a nearly 5-fold higher risk of hyperkalemia,115 likely
caused by pronounced decreases in circulating aldosterone levels.
The compensatory increase in renin release in the setting of ACE inhibitor and/or ARB
therapy has also prompted trials of direct renin inhibitors (DRIs) in patients with HF. It was
postulated that renin inhibition would augment downstream RAAS blockade and provide
additive benefits when combined with ACE inhibitor or ARB therapy. Although the DRI
aliskiren reduces plasma renin activity, there is no evidence of a clinical benefit in HF. In
ASTRONAUT (Aliskiren Trial on Acute Heart Failure Outcomes), a large randomized
controlled clinical trial of patients on optimal HF therapy (including other RAAS
antagonists), aliskiren failed to reduce a composite of cardiovascular death or
hospitalizations and was associated with hypotension, renal dysfunction, and
hyperkalemia.116 ATMOSPHERE (Aliskiren Trial of Minimizing Outcomes for Patients
with Heart Failure), a trial comparing aliskiren with enalapril in patients with HF is
underway.117
NATRIURETIC PEPTIDES AND CARDIOVASCULAR PHYSIOLOGY
The natriuretic peptides (atrial natriuretic peptide [ANP], B-type natriuretic peptide [BNP],
and C-type natriuretic peptide [CNP]) collectively produce adaptive effects in HF and
oppose the actions of the effector hormones of the SNS and RAAS. ANP is released by cells
in the atrial wall in response to stretch or increases in plasma Ang II, ET-1, and
vasopressin.118 BNP is released primarily from the left ventricle, although atrial cells also
release BNP at a much lower concentration than ANP.119 CNP is released by endothelial
cells in response to increased cytokines and other hormones such as acetylcholine.120 ANP,
BNP, and CNP bind to 2 transmembrane-bound guanylyl cyclases (GCs), GC-A and GC-B,
to increase intracellular cyclic guanosine monophosphate (cGMP) and elicit wide-ranging
physiologic effects including vasodilation, increased salt and water excretion, decreased
renin release, dampened SNS activity, decreased cardiac fibrosis, and blunted
cardiomyocyte hypertrophy.121–125
Targeting Natriuretic Peptides for HF Therapy
Nesiritide is a recombinant form of BNP that binds GC receptors on vascular endothelium
and in the kidney. Nesiritide mimics the salutary effects of endogenous BNP on
cardiovascular hemodynamics and renal physiology, but does not reduce symptoms to a
significantly greater extent than diuretics and vasodilators.126 In large clinical trials,
nesiritide did not improve survival, although early concerns over increased mortality and
worsening renal function have subsided.
BNP has a short plasma half-life because of its removal by cellular reuptake, the natriuretic
peptide clearance receptor (GC-C), and breakdown by neprilysin, the same enzyme that
generates Ang(1–7) from Ang I.127 Neprilysin inhibitors have been developed in an attempt
to increase the half-life of circulating BNP for therapeutic benefit, although they typically
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also have been designed to antagonize RAAS in order to counter the unfavorable effects of
decreased Ang(1–7) levels. Omapatrilat, a vasopeptide inhibitor of both neprilysin and ACE,
exerted favorable hemodynamic effects, but was associated with a more than 3-fold increase
in angioedema compared with an ACE inhibitor, likely caused by its inhibition of both
bradykinin and substance P degradation.128 The focus has since shifted to compounds that
both inhibit neprilysin and block Ang II receptors. A study comparing enalapril and
LCZ696, a dual neprilysin inhibitor and ARB, in chronic HF is underway.129
VASOPRESSIN IN HF PATHOPHYSIOLOGY AND PHARMACOTHERAPY
Vasopressin (arginine vasopressin [AVP]) is released in response to increased osmolarity,
Ang II, or SNS stimulation, and is chronically increased in HF.130 AVP is secreted primarily
from the posterior pituitary, but local vasopressin production may also contribute to the
progression of HF.131 Vasopressin stimulates the activity of 3 G protein–coupled receptors,
V1a, V1b, and V2. V1a, expressed on vascular smooth muscle and ventricular myocardium,
couples to Gq, increasing intracellular calcium and causing vasoconstriction, positive
inotropy, and hypertrophy.132 The V2 receptor mediates free water reabsorption in the
kidney. Excess stimulation can lead to hypervolemic hyponatremia in patients with HF.
Recognition that AVP secretion is upregulated in HF prompted investigations of vasopressin
receptor antagonists (VRAs) as another novel therapeutic strategy. Despite aggressive
diuretic therapy, many patients with HF continue to retain excess free water and
hyponatremia is common. However, whether hyponatremia represents a target of
pharmacologic therapy or a surrogate marker for the severity of disease remains an area of
controversy. VRAs competitively inhibit V2 receptors in renal collecting ducts, thereby
preventing the reabsorption of free water. Tolvaptan, an oral VRA, is selective for V2
receptors, whereas intravenous conivaptan also inhibits V1A receptors. In EVEREST
(Efficacy of Vasopressin Antagonism in Heart Failure Outcome Study with Tolvaptan),
tolvaptan conferred improvements in some HF symptoms, but did not improve survival.133
Although tolvaptan partially corrects hyponatremia, the effect is not durable after
discontinuation of therapy.134 The reasons for the modest clinical impact of this
physiologically rational therapeutic approach are unclear.
SUMMARY
The depth to which disease mechanism is understood is often dictated by extant
technologies. In that respect, the conception of HF was informed successively by gross
anatomy, organ-level physiology, and cellular physiology. As outlined in this review, recent
advances have enabled an expansion in knowledge of the cellular and subcellular
mechanisms that underlie the characteristic neurohormonal disturbances in HF. How will
today’s emerging technologies influence understanding of HF? Will massively parallel
sequencing technologies inform clinicians that HF fundamentally is a disease of genetic and
epigenetic modifications?135,136 Will the next generation of HF therapies target DNA
methylation? Epigenetic reader proteins?137 Noncoding RNAs or microRNAs?138 As
always, only time will tell.
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• Neurohormonal abnormalities are central to the pathobiology of heart failure
and antagonism of their systemic effects is the basis of contemporary heart
failure pharmacotherapy.
• β-Blockers likely confer benefit through induction of reverse remodeling,
reduction of sudden cardiac death, and restoration of adaptive adrenergic
signaling.
• Antagonists of the renin-angiotensin-aldosterone system have beneficial
activities in cells of the heart in addition to their effects in the kidneys and
peripheral vasculature.
• All agents that improve survival in heart failure target neurohormones, but not
all neurohormonal modulators improve survival.
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SNS effector hormones and adrenergic receptor subtypes in cells of the (A) heart and (B)
peripheral vasculature.
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RAAS effector hormones and receptors in cells of the (A) heart and (B) peripheral
vasculature. Aldo, aldosterone.
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Table 2
Beneficial effects of neurohormonal antagonists in clinical trials of HF pharmacotherapy



















Abbreviations: ACS, acute coronary syndrome; ARB, angiotensin receptor blocker; EF, ejection fraction; ICD, implantable cardioverter
defibrillator; SCD, sudden cardiac death.
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